Colorectal Cancer Alliance’s Post

The U.S. Food and Drug Administration has granted accelerated approval for Krazati (adagrasib) in combination with cetuximab as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer (CRC) who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, according to manufacturer Bristol Myers Squibb. Read more about this on our blog 👉 https://lnkd.in/gRF9UYWj

  • No alternative text description for this image
Karlene Shaw MPH

Patient Account Specialist at UnitedHealth Group

2w

Great!!!!!!!!!!!!!!!!!!!!!!! I wish I could work for this awesome company and help to sell some of these treatments. Colorectal Cancer is curable when diagnosed early.

To view or add a comment, sign in

Explore topics